Inovio Pharmaceuticals (INO.Q) announced the publication of the preclinical study data for its COVID-19 DNA vaccine, IN0-4800, demonstrating neutralizing antibody and T-cell immune responses against
When the history books are written on this passage of our lives, under pandemic lockdown and with once-in-three-generations levels of unemployment, they’ll note that in
Naturally Splendid (NSP.T) signed an LOI with Vancouver-based Biological Pharmamedical Research to form a joint venture to continue developing and pursuing phase two clinical studies,
Here’s a simple and effective investment strategy: invest in companies that sell
products with growing inelastic demand.
Champignon Brands (SHRM.C) recent term sheet with California-based Wellness Clinic of Orange County not only furthers the company’s North American clinical expansion, but gives them
We’re two months in on this pandemic and governments are thinking about reopening the economy for the summer when the traditional flu season winds down.
We’ve all seen it: the media craze about gluten and how it’s terrible for us. Except it generally lacks solid scientific consensus, and like most
“Let them say what they want, we know what we’re doing, and we’re doing the work,” Michael Frank told me a month ago, as he
Neptune Wellness Solutions (NEPT.T) reported today that their phase II expansion at their Sherbrooke, Quebec, facility is online and has received approvals to run product
Oddball pharmaceutical player Revive Therapeutics (RVV.C) found itself on the back end of a warning by the BCSC this week, that certain German players in the smallcap promotion space had over-hyped the mushroom/cannabis/biotech deal and promised big wins inappropriately for anyone who invested. As a marketing partner of Revive, I got a few panicky texts from certain folks wondering if that meant trouble for us – or them. It’s not a problem for us; our coverage has been appropriately even-handed.
Mind Medicine (MMED.E) started enrolling candidates for further human safety trial studies of 18-MC, the company’s orally taken ibogaine derivative for the treatment of opioid
Being working class in the United States in the time of Donald Trump is a curious endeavour. The stories coming from some of my friends
When new sectors emerge, as cannabis did in 2013 and psychedelics are doing right now, microcap companies that have struggled in other sectors will often pivot into new business. Miners become weed companies, then biotech companies, then shroom companies, as boards and management pursue new opportunities that might one day prove better than the last.
Roadman Investments’ (LITT.V) recent acquisition target CLOV Biopharma (CBP) is continuing its research into the potential commercial uses of cedar leaf oil vapour (CLOV), specifically
Soligenix (SNGX.Q), a biopharma company that develops and commercializes products for rare diseases, announced that its RiVax, which is a heat stable ricin toxin vaccine,
If you’ve had your eye off the biotech sector recently because it doesn’t directly involve gold or cannabis, you’re missing out on one of the
Xphyto (XPHY.C) is dominating the cannabis sector like Sean Kemp used to dominate the Seattle buffet scene. It’s a legit beast right now, jumping from
The first time we dealt with a coronavirus I was a lonely college student in Oshawa, Ontario and folks around me thought briefly that the
Eli Lilly and company (LLY.NYSE) and robotic cloud-computing provider, Strateos, unveiled the Lilly Life Sciences Studio lab, a new robotic laboratory in San Diego, Calfornia,
Amgen (AMGN.Q) signed a lease with BioMed Realty for a new 240,000 square foot Leadership in Energy and Environmental Design (LEED) candidate facility in the
December 9, 2019 – “Merger Monday” – a couple of Big Pharma companies announced plans to acquire two cancer-focused biotechs – in separate deals worth
When markets closed Friday November 15, Karuna Therapeutics (KRTX.Q) was just another pharma-stock trading in the mid-teens trying to make drugs for patients with Alzheimer’s
Johnson & Johnson (JNJ.NYSE) issued a recall for a single lot of its Baby Powder in response to a FDA test that uncovered the presence
My best friend growing up married a woman with severe rhinosinusitis and nasal polyps. That sounds about as serious as a case of the common
Cannabis has been good to us here at equity.guru. There are 1,283 pages of cannabis-related content on our site and it’s still growing. That said,
Last minute attendees can register for Cambridge House’s Extraordinary Future event here and use promocode: FUTURE30 for 30% off. The Extraordinary Future Conference – running
“Cannabis is dead; long live cannabis.” Mushrooms, mark my words.. –Ancient potstocks proverb Seriously though, folks, the cannabis sector is in trouble. Take a look
China has a bug up its ass about U.S. and Canada’s new permissive cannabis laws. Is anyone surprised? Apparently, our new easygoing attitude towards cannabis
An Oklahoma district court judge has ordered Johnson & Johnson (JNJ.NYSE) to pay $572 million for its part in the state’s opioid epidemic. Cleveland County
We all know someone who’s been touched by cancer. It’s been called the worst scourge of civilized mankind. It sweeps through a family, disrupting our
GW Pharmaceuticals (GWPH.Q) has received a recommendation from the European Medicines Agency (EMA) for the authorization of the company’s Epidyolex cannabis oral solution for use
Someone in the world develops dementia every three seconds. Alzheimer’s disease and other dementia-related disorders affect 50M people around the world and that number is
According to the World Health Organization, around 50 million people suffer from dementia worldwide and nearly 10 million new cases are diagnosed every year. Alzheimers
World Class Extractions (PUMP.C), a newcomer in the extraction sector, signed an LOI to acquire Quadron Cannatech (QCC.C) today. This acquisition will put World Class
The push is on for Yield Growth’s (BOSS.C) subsidiary, Urban Juve, as it increases its market penetration by another 24 stores through a partnership with
GTEC Holdings (GTEC.V) subsidiary Alberta Craft Cannabis is now operating at full capacity and their product is in high demand. Alberta Craft just completed its first
What makes this cannabis market really exciting is that it’s largely uncharted territory. When cannabis went live last October, it opened the door for growers,
Infused MFG, a subsidiary of 1933 Industries (TGIF.C), announced a sponsorship agreement with mixed martial arts (MMA) fighter Sarah Moras earlier this week. This accompanied the
GTEC Holdings (GTEC.V) is pumping up its brokered private placement to $8 million. The company announced Feb. 25 that heavy demand drove the need to
Oxycontin, once pitched as a treatment for chronic pain, is now synonymous with the opioids currently plaguing Canada and the United States. In the U.S.
Titan Pharmaceuticals (TTNP.Q) is an American pharmaceutical company based out of San Francisco, California. The company has recently relaunched Probuphine, its six-month treatment for Opioid Use
by Guy Bennett Christmas Eve, 2018 – I’m writing this from a hospital bed in a hard scrabble town in the mountains of Yunnan Province,
Isodiol International (ISOL.C) is poised for a successful 2019 thanks to approved or anticipated regulatory changes regarding hemp in the US and Mexico. Industrial hemp is
Licensed producer VIVO Cannabis (VIVO.V) is a serious player in the Canadian cannabis sector which isn’t getting the attention it deserves. The company’s $300 million
To tell this story in 25 words or less would be to do it a terrible injustice, so I’ve sat on it for a bit,
TGOD’s (TGOD.T) is providing substantive updates on its operations, detailing the company’s Mexican and European expansion, the latest round of financing and additions to its
GTEC Holdings (GTEC.V) has signed a binding LOI with a wholesale pharmaceutical distributor following Health Canada’s landmark approval of Canada’s largest pharmacy’s to dispense medical
Now that Amazon is LITERALLY Taking Over The Post Office, You May Also Like VANC Pharma, The Detour Selloff Continues, Major Supply Concerns light Up
Transitioning from a capital markets CEO to a pharma CEO is a smart move for a licensed cannabis producer about to rapidly expand its output,
At Equity Guru, we sometimes get news before it hits the street. Such is the case with a company called X-Sprays – which is so
In 1856 a 34-year old French microbiologist named Louis Pasteur discovered that heating wine stopped it going bad. Through scientific experimentation Pasteur determined the optimum
I remember the first time BlueOcean NutraSciences (BOC.V) came to my boardroom. They were amped over something that, they were certain, was going to turn
The weed business has one major bottleneck that screws up all business that comes before it. Wanna know what it is? It’s this: The positive
A round of applause to the compliance officers at the ASX, who have finally pulled their finger out and called bullshit on the last 6
Another day, another new cannabinoid clinic for the boffins at Canabo Medical (CMM.V): this one adding to their tally in Ontario with a new facility
On the back of our recent piece about the implosion of Stemcell United (which has cratered a further 33% since we released the article) we
Vinergy Resources (VIN.C) may still sound like a mining company, but the innovative CBD product development house acquiring MJ Biopharma is neck deep in its
There were a lot of bummed out investors when VANC Pharmaceuticals rolled back their share base recently, but the dip has brought about a very
So how do you want to handle the next few years of political madness and megalomania? War might be around the corner, revolution not far
Prepare for the next great Canadian marijuana wave. Going against popular wisdom (and, admittedly, what I’ve been saying for a year now could never happen),
I guessed Emblem would drop at around $200m and wasn’t far off, but what’s been most impressive about the next big marijuana deal’s drop into
Emblem Cannabis (EMC.V) hasn’t had to be loud about it. The Canadian investor base has been calling and pleading and goading and pushing to get
Typical. Not one to let an opportunity pass by without grabbing another damn asset, Marc Lustig at CannaRoyalty (formerly Cannabis Royalties) today announced his company’s
I love it when I get to use the phrase ‘company maker’, but it doesn’t happen so often. Today, Canabo Medical (CMM.V) got to pull
Canabo Medical (CMM.V) is new to the Canadian markets, but it’s making waves in terms of its business plan, which is anything but typical. Running
A year back, I was hitting the medical marijuana sector pretty hard in terms of coverage, writing regularly about everyone from the giants in the
In the spirit of ‘where are they now’ day comes another in my trilogy of companies I used to write about a lot, that I
Biotech flailer Hemostemix (HEM.V) took a punch to its distended gut today as a sell-off of the embattled stock cut the share price of the
Telesta (TST.T) will cease to exist should shareholders agree to an all-share deal offered by Prometic Life Sciences (PLI.T) for the company’s Belleville, Ontario vaccine
Timeline: Mid 2015 – Laguna Blends (LAG.C) says, we’re coming. CEO lends company money. Market yawns. Late 2015 – Laguna Blends says, Naturally Splendid (NSP.V)
Things you don’t want to see from your speculative drug research company stock: [Bellus Health] (BLU.T), a drug development company focused on rare diseases, today
When I was running the editorial show at Stockhouse, I had reason to look over a lot of messageboards for a wide variety of public
Lots of weedness to discuss today folks, so let’s start with the most confusing of the lot. Golden Leaf Holdings (GLH.C) is a company I
Busy next few days as I’m going to ground to ferret out some new stories. As is tradition, I like to tell you ahead of
Last December, Canadian Liberal Party mover/shaker, founding partner in Canopy Growth Corporation (CGC.V) and private equity player Chuck Rifici bought Wikileafs, the best named dispensary
The only thing I knew about Zomedica (ZOM.V) prior to their launch on the TSX Venture Exchange Tuesday was 1) former Stockhouse eastern sales goddess
Welcome to the weekend news dump. The news dribbling out on a weekend is usually the stuff companies want to bury, and there’s been a
Politics is a harsh mistress, but it gets considerably harsher when the ruling party decides to let anarchy reign because it suits their plans for
Back when Vanc Pharmaceuticals (NPH.V) rolled out last year, a decent marketing push was resisted in many quarters by retail investors who just didn’t believe
In our latest podcast, Dr. Lui Franciosi has chops in the pharma game, but the collection of professors emeritus, leaders in biochemistry, cancer research gods,
Cannabis research play Veritas Pharmaceuticals (VRT.C) announced news after yesterday’s close, as predicted here at Equity.Guru, and the news was most definitely good. If you’re
Busy day prowling the halls of Vancouver’s brokers today, jamming CEO meetings from 8am through to a few minutes ago. Caught up with the crews
Had a long and detailed discussion last night with the very busy CEO of Veritas Pharma (VRT.C)*, Dr. Lui Franciosi, and came away pretty impressed with
Great morning if you’ve been doing your due diligence through Equity Guru – some of our favourites have been jumping today by 20% or more.
Today marks the end of the first week of Equity Guru’s legit existence, and it’s been a beauty. First, we’ve signed enough sponsor deals to
Regular readers (of my as yet un-launched site) will know I’ve been talking to Veritas Pharma (VRT.C) over the last few weeks. I’m liking the
Just kidding. Nothing can fix Valeant Pharmaceuticals (VRX.T). Canada’s Big Pharma Clown Car has been in an out of congressional committees wondering why it charges
